Overview

Masitinib Plus Gemcitabine in Pancreatic Cancer

Status:
Completed

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

The objective is to compare efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine, in treatment of patients with locally advanced or metastatic pancreatic cancer and who have pain related to the disease.

Phase:

Phase 3

Details

Lead Sponsor:

AB Science

Treatments:

Gemcitabine